Dyne Therapeutics
About: Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Employees: 191
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
10% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 62
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
1% less funds holding
Funds holding: 201 [Q3] → 199 (-2) [Q4]
1.91% less ownership
Funds ownership: 111.57% [Q3] → 109.65% (-1.91%) [Q4]
30% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 7 (-3) [Q4]
35% less capital invested
Capital invested by funds: $4.02B [Q3] → $2.63B (-$1.39B) [Q4]
65% less call options, than puts
Call options by funds: $3.57M | Put options by funds: $10.3M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
44%
upside
Avg. target
$44
269%
upside
High target
$50
324%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
JP Morgan Tessa Romero 23% 1-year accuracy 3 / 13 met price target | 44%upside $17 | Neutral Maintained | 21 Mar 2025 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 110 / 353 met price target | 290%upside $46 | Buy Reiterated | 17 Mar 2025 |
Chardan Capital Keay Nakae 18% 1-year accuracy 13 / 73 met price target | 324%upside $50 | Buy Maintained | 17 Mar 2025 |
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target | 324%upside $50 | Outperform Initiated | 12 Mar 2025 |
Scotiabank Louise Chen 27% 1-year accuracy 32 / 118 met price target | 324%upside $50 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion
Based on 3 articles about DYN published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commission (EC) has granted orphan drug designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD).
Neutral
GlobeNewsWire
2 weeks ago
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne.
Neutral
GlobeNewsWire
2 weeks ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne's Compensation Committee and made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J.
Neutral
GlobeNewsWire
1 month ago
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -
Neutral
GlobeNewsWire
1 month ago
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 - WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose).
Positive
Seeking Alpha
1 month ago
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1, expected in the 1st half of 2026. With positive data released from phase 1/2 ACHIEVE study, plus FDA allowing splicing correction as a surrogate biomarker, it sets up a possible Accelerated Approval filing of DYNE-101 in 2026.
Positive
Benzinga
1 month ago
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc., focused on developing therapies for genetically driven neuromuscular diseases.
Neutral
GlobeNewsWire
1 month ago
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Received FDA Fast Track Designation for DYNE-101 in DM1 - - Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD Planned for Q1 2025 to Support Submission for U.S. Accelerated Approval - WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.
Charts implemented using Lightweight Charts™